A Roadmap for Future Parkinson’s Pharmacogenomics in Asia

Muhammad Akbar1*, Gita Vita Soraya1,2, Zulvikar Syambani Ulhaq3 and Andi Kurnia Bintang1

1 Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia, 2 Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia, 3 Research Center for Pre-Clinical and Clinical Medicine, National Research and Innovation Agency Republic of Indonesia, Cibinong, Indonesia

Keywords: Parkinson’s disease, pharmacogenomics, Asia, genetics, polymorphism

INTRODUCTION

Parkinson’s disease (PD) remains one of the most debilitating neurodegenerative diseases, with increasing prevalence worldwide. Due to the demographic transition ongoing in many countries, life expectancy is increasing, whilst chronic and degenerative conditions such as Parkinson’s also rise with aging (Dorsey et al., 2018). The disease is typically seen in persons 60 years of age or older who are already more likely to experience additional burden due to limited physical, cognitive, and emotional capacity in their day-to-day lives. However, it is notable that earlier onset of the disease have been identified in a small subset of patients (Post et al., 2020). When left untreated, PD can exert a negative long-term impact on the quality of life of both the patient and the caregiver (Asimakopoulos et al., 2008).

Although Asia had the largest number of PD incidence in 2019, a lower prevalence of PD has been documented in Japan and Singapore, despite having a relatively high proportion of aged individuals. Moreover, it is notable that sex-related differences have been reported in PD prevalence, clinical phenotypes, and prognosis. Hence, these findings pinpoint that genetic and environmental risk factors may play an important role to the differences observed in the region.

PHARMACOGENETICS AND PD

Over the past few decades, we have seen rapid development of genetic explorations in PD, mainly due to advances in genotyping technology such as next generation sequencing, in addition to the rising number of genome wide association studies. Initially, genetic exploration in PD aimed to identify causative genetics or the genetic architecture of the condition, with first discoveries focused on the autosomal dominant and recessive mutations in PD (SCNA, LRRK2, VPS35 and PINK1, DJ-1, Parkin genes) and environment-gene interactions in the pathobiology of PD (Lill, 2016). The work has since extended in to pharmacogenetic profiling in PD,
especially regarding the genetic basis of levodopa induced complications to determine whether certain gene polymorphisms can increase an individual’s chance of experiencing ineffective levodopa treatment (Espay et al., 2018; Kalinderi et al., 2019; Falla et al., 2021; Soraya et al., 2022). This is supported by improved bioinformatics tools such as the PharmCAT (Pharmacogenomics Clinical Annotation Tool) (Klein and Ritchie, 2018), or pharmacogenetic and pharmacogenicomic databases such as the Pharmacogenomics Knowledge Base (PharmGKB) (Hewett et al., 2002), and the CPIC database (Relling and Klein, 2011) that provide peer-reviewed information on gene/drug pairs.

Hence, numerous gene polymorphisms have been associated with the occurrence of these motor complications, a majority of which are involved in the dopamine metabolic and signaling pathways, including polymorphisms of the dopamine transporter/solute carrier-6 (DAT/SLC6) genes responsible for trans-membrane dopamine transport (Purcaro et al., 2019), and those that encode dopamine receptor families D1 (DRD1, DRD5) and D2 (DRD2, DRD3, DRD4) (Rieck et al., 2012; Kaplan et al., 2014; Dos Santos et al., 2019). Interestingly, a large subset of these gene polymorphisms are not only highly prevalent in Asians, but also demonstrate stronger associations in the Asian population. An example is the COMT rs4680 and rs4633 which in our previous meta-analysis was found to be markers of dyskinesia in Asian ethnicities (Soraya et al., 2022). Together, these imply that genetic aspects are crucial in order to elucidate regional characteristics.

It is clear that in this new era of PD management, we are equipped with technological support and research advancements on PD pharmacogenetics. Which then brings us to the question of what can be done next to accelerate the clinical implementations? Whilst many predict that implementation is still a long road ahead, particularly in resource poor settings, there is definitely a high likelihood of translation, seeing the success of previous pharmacogenetic screening practices. Therefore, it is vitally important to understand an inter-ethnic difference as the fields enters the era of genetics-based targeted therapies.

DISCUSSION

In this opportunity, we would like to propose a roadmap for future implementation of Parkinson’s pharmacogenomics particularly in Asia. Firstly, more clinical trials need to be performed to confirm the associations using pharmacogenetic endpoints as the outcome, such as the occurrence of LID or MF. There are several issues with current evidence, mainly due to the limited sample size and the clinical heterogeneity that subjects present with. The potential variance across populations require careful consideration, and we propose that the trials for Asian populations need to be performed and also consider the differences between Asian ethnicities. In fact, the establishment of initiatives such as the South East Asian Pharmacogenomics Research Network (SEAPharm) by member countries Korea, Indonesia, Malaysia, Taiwan, and Thailand can be valuable in assisting the strengthening pharmacogenomics research and the advancement of pharmacogenetics testing within the region (Chumnumwat et al., 2019).

Aside from improving the evidence on clinical robustness, more effort needs to be done in assessing cost-effectivity. In particular, how does the cost of testing fare against the cost of treating side effects and against the cost of additional patient visits or hospital stays. Several studies have assessed the cost-effectivity of pharmacogenetic testing for implementation of warfarin pharmacogenetic testing (Ma and Lu, 2011) and for carbamazepine hypersensitivity (Chen et al., 2016). These illustrate that more effort need to be made to realize strategies to improve the cost-effectivity of implementation. Along with assessing clinical validity and cost-effectivity, we also need to initiate awareness of the pharmacogenetics and precision medicine, not only amongst physicians but also for patients. Moreover, discussions should also continue regarding the ethical and social issues associated with implementation of pharmacogenetic testing in the disease population.

The acquirement of robust evidence then needs to be supported by guidelines from regulatory bodies regarding the pharmacogenetic profile of levodopa. This reflects previously successful pharmacogenomics screening such as HLA-B*15:02 for carbamazepine hypersensitivity, in which the pharmacogenetic side effect was clearly listed by the FDA. Currently, several consortiums have been set up to speed translation and supervise recommendations, such as the Clinical Pharmacogenetics Implementation Consortium, (CPIC), which are capable of releasing guidelines regarding the clinical implementation (Relling and Klein, 2011).

In conclusion, a united effort is needed to speed up the clinical implementation of pharmacogenomics in PD, especially in low resource settings such as Asia. This involves synchronic effort to improve clinical validity, increase accessibility to affordable genotyping platforms, establish cost-effectivity, and the design and implementation of appropriate regulations. Moreover, epidemiological as well as genetic studies in the Asian region would better advance understanding of PD characteristics in order to develop better approaches to overcome PD.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES

Asimakopoulos, P., Caslake, R., Harris, C. E., Gordon, J. C., Taylor, K. S. M., and Counsell, C. (2008). Changes in quality of life in people with Parkinson’s disease left untreated at diagnosis. J. Neurol. Neurosurg Psychiatry. 79, 716–718. doi: 10.1136/jnp.2007.137190

Chen, Z., Liew, D., and Kwan, P. (2016). Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 86, 1086–1094. doi: 10.1212/WNL.0000000000002484
Chumnumwat, S., Lu, Z. H., Sukasem, C., Winther, M. D., Capule, F. R., and Hamid, A. A. A. (2019). Southeast asian pharmacogenomics research network (SEAPharm): current status and perspectives. Public Health Genom. 22, 132–139. doi: 10.1159/000502916

Dorsey, E. R., Elbaz, A., Nichols, E., Abd-Allah, F., Abdelalim, A., and Advan, J. C. (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939–953. doi: 10.1016/S1474-4422(18)30295-3

Dos Santos, E. U. D., Duarte, E. B. C., Miranda, L. M. R., Asano, A. G. C., Asano, N. M. J., and Maia, M., d. e. M. D. (2019). Influence of DRD1 and DRD3 polymorphisms in the occurrence of motor effects in patients with sporadic Parkinson’s disease. Neuromolecular Med. 21, 295–302. doi: 10.1007/s12017-019-08549-3

Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., and Fox, S. H. (2018). Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann. Neurol. 84, 797–811. doi: 10.1002/ana.25364

Falla, M., Fonzo, D., i, Hicks, A., Pramstaller, A. A., Fabbrini, P. P., and Genetic, G. (2021). variants in levodopa-induced dyskinesia (LID): a systematic review and meta-analysis. Parkinsonism Relat. Disord. 84, 52–60. doi: 10.1016/j.parkreldis.2021.01.020

Hewett, M., Oliver, D. E., Rubin, D. L., Easton, K. L., Stuart, J. M., and Altman, R. B. (2002). PharmGKR: the pharmacogenetics knowledge base. Nucleic. Acids Res. 30, 163–165. doi: 10.1093/nar/30.1.163

Kalinderi, K., Papalagkas, V., and Fidani, L. (2019). Pharmacogenetics and levodopa induced motor complications. Int. J. Neurosci. 129, 384–392. doi: 10.1080/00216411.2018.1538993

Kaplan, N., Vituri, A., Korczyn, A. D., Cohen, O. S., Inzelberg, R., and Yahalom, G. (2014). Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease. J. Mol. Neurosci. 53, 183–188. doi: 10.1007/s12031-014-0276-9

Klein, T. E., and Ritchie, M. D. (2018). PharmCAT: a pharmacogenomics clinical annotation tool. Clin. Pharmacol. Ther. 104, 19–22. doi: 10.1002/cpt.928

Lill, C. M. (2016). Genetics of Parkinson’s disease. Mol. Cell Probes. 30, 386–396. doi: 10.1016/j.mcp.2016.11.001

Limousin, P., and Foltynie, T. (2019). Long-term outcomes of deep brain stimulation in Parkinson disease. Nat. Rev. Neurol. 15, 234–242. doi: 10.1038/s41582-019-0145-9

Ma, Q., and Lu, A. Y. (2011). Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 63, 437–459. doi: 10.1124/pr.110.003533

Post, B., van den Heuvel, L., van Pooije, T., van Ruisen, X., van de Warrenburg, B., and Nonnekes, J. (2020). Young onset Parkinson’s Disease: a modern and tailored approach. J Park Dis. 10, S29–36. doi: 10.3233/JPD-202135

Purcaro, C., Vanacore, N., Moret, F., Battista, D., i, Rubino, M. E., and Pierandrei, A. (2019). S, et al. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson’s disease. Neurosci. Lett. 690, 83–88. doi: 10.1016/j.neulet.2018.10.021

Relling, M., and Klein, T. (2011). CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464–467. doi: 10.1038/clpt.2010.279

Rieck, M., Schumacher-Schuh, A. F., Altmann, V., Francisconi, C. L., Fagundes, P. T., and Monte, T. L. (2012). DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson’s disease patients. Pharmacogenomics. 13, 1701–1710. doi: 10.2217/pgs.12.149

Schulz-Schaeffer, W. J. (2010). The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol (Berl). 120, 131–143. doi: 10.1007/s00401-010-0711-0

Soraya, G. V., Ulhaq, Z. S., Shodry, S., Araaf Sirojan Kusuma, M., Herawangsa, S., Sativa, M. O., et al. (2022). Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson’s disease: a systematic review and meta-analysis. Neurol. Sci. 1–22. doi: 10.1007/s10072-021-05829-4. [Epub ahead of print].

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.